Skip to main content

Table 5 Association between CD30 expression and clinicopathologic features of patients with extranodal natural killer/T-cell lymphoma, nasal type

From: CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China

Variable

CD30 expression [cases (%)]

P value

Positive

Negative

Total

43

48

 

Age (years)

  

0.508

 ≤60

37 (40.6)

44 (48.4)

 

 >60

6 (6.6)

4 (4.4)

 

Sex

  

0.675

 Male

33 (36.3)

35 (38.5)

 

 Female

10 (10.9)

13 (14.3)

 

B symptoms

  

0.627

 Yes

21 (23.1)

21 (23.1)

 

 No

22 (24.1)

27 (29.7)

 

Ki-67 index

  

0.060

 ≤50

14 (15.4)

25 (27.5)

 

 >50

29 (31.8)

23 (25.3)

 

Primary site

  

0.720

 Upper aerodigestive tract

37 (40.6)

40 (44.0)

 

 Others

6 (6.6)

8 (8.8)

 

Ann-Arbor stage

  

0.080

 I/II

37 (40.6)

34 (37.4)

 

 III/IV

6 (6.6)

14 (15.4)

 

LDH level

  

0.894

 Elevated

12 (13.2)

14 (15.4)

 

 Normal

31 (34.0)

34 (37.4)

 

Therapeutic modality

  

0.230

 Chemotherapy alone

10 (10.9)

19 (20.9)

 

 Chemoradiotherapy

31 (34.0)

27 (29.7)

 

 Radiotherapy alone

1 (1.1)

1 (1.1)

 

 Chemotherapy plus surgery

1 (1.1)

0 (0.0)

 

 Unavailable

0 (0.0)

1 (1.1)

 

EBV-DNA status

  

0.602

 Positive

19 (20.9)

20 (22.0)

 

 Negative

18 (19.8)

24 (26.3)

 

 Unavailable

6 (6.6)

4 (4.4)

 

Relapse

  

0.657

 Yes

19 (20.9)

19 (20.9)

 

 No

24 (26.3)

29 (31.9)

 
  1. LDH lactate dehydrogenase, EBV Epstein-Barr virus